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mucoepidermoid carcinoma of the
major salivary glandsJan-Dirk Ragusea,*, Hans Joachim Gatha, J€urgen Biera,
Hanno Riessb, Helmut OettlebaKlinik f€ur Mund-, Kiefer- und Gesichtschirurgie, Klinische Navigation und Robotik,
Plastische Operationen, Charite Universit€atsmedizin Berlin, Campus Virchow Klinikum
Augustenburger Platz 1, 13353 Berlin, Germany
bInnere Klinik m. Schwerpunkt f€ur H€amatologie und Onkologie, Charite Universit€atsmedizin
Berlin, Campus Virchow Klinikum Augustenburger Platz 1, 13353 Berlin, GermanySummary Malignant tumours of the salivary gland are rare entities and are treated
primarily surgical. Recurrent salivary gland malignancies present difficult therapeutic
decisions and in many instances poor prognosis. Four pre-treated patients with
relapse of high grade mucoepidermoid carcinoma originating in the major salivary
glands presented in our clinic with extended tumours. Chemotherapy was initiated
with docetaxel (Taxotere) 100 mg/m2. After six cycles two complete remissions and
two partial remissions were achieved. Al patients remained stable for at least 18
months. Docetaxel in the context of recurrent salivary gland cancer is a viable
option.c 2003 Elsevier Ltd. All rights reserved.
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Malignant primary tumours of the major salivary
gland are uncommon. They represent 3–5% of all
head and neck neoplasms.1;2 The parotid gland is the
single most common site for any salivary gland
neoplasm, followed by the submandibular and the
sublingual gland. The frequency of malign lesions
varies from site to site and are seen in 15% in the
parotid and in 40% in the submandibular gland.3 The
most common malignant salivary gland tumour is* Corresponding author. Tel.: +49-30-450-555022; fax: +49-30-
450-555901.
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promises about 10% of all tumours followed by the
adenoid cystic carcinoma and adenocarcinoma. MEC
displays a variety of biological behaviours. Low
grade tumours can have a long natural history and
rarely metastasise, while the high grade counter-
parts can be very aggressive and prone to local
invasion and early metastasis.4 Treatment is pre-
dominantly surgical and improved irradiation con-
cepts have made loco-regional tumour control
possible for an increasing number of patients.5;6
Chemotherapy has been given in locally advanced,
metastatic or recurrent disease. In case of tumour
relapse response rates for single agents or combi-
nation chemotherapy (Cisplatin, 5-FU, Doxorubicin,
Paclitaxel, Vinorelbine) vary between 10 and 46%,ved.
Table 1 Patient characteristics
Sex Age Primary tumour Time to
relapse
(month)
Recurrence Response Lasting of
response
(month)
Site Stage Size (cm) Infiltration
Male 67 Submandibular T2 N1 M0 6 4 · 2 Mandible CR 27
Male 55 Parotid T3 N0 M0 6 4 · 2 Skin PR 22
Male 58 Parotid T2 N0 M0 12 3 · 3 Mandible CR 20
Female 60 Parotid T3 N1 M0 6 6 · 3 Mandible PR 18
6 J.-D. Raguse et al.but this response is of short duration, which under-
lines the palliative character of the treatment.7;8Patients and methods
Between 2000 and 2001, four patients with
recurrent MEC in the head and neck area presented
in our clinic. Three patients had primary tumours
of the parotid gland, one patient suffered from
MEC of the submandibular gland. Patients’ char-
acteristics are shown in Table 1. All patients
showed extensive tumours infiltrating the skin in
one and the mandible in three cases. Patients had
been previously treated by surgery consisting of
radical resection of the primary tumour with clear
margins, neck dissection and postoperative irradi-
ation to 66Gy. The time between first treatment
and relapse varied from 6 to 12 months. Biopsy
confirmed the diagnosis of recurrent high grade
MEC in all these patients. Systemic chemotherapy
was initiated with six cycles Docetaxel 100/m2 over
1 h given every 21 days.Table 2 Reported response rates to chemotherapy
in recurrent salivary gland cancerResults
Therapy was well tolerated. Highest toxicity was
leukopenia grade 2 according to WHO. No other
haematologic toxicity occurred and no febrile
neutropenia was seen. In one patient an ongoing
paresthesia in fingers and toes occurred but did
not hamper the patient. All patients showed radio-
logical tumour response. There was complete re-
sponse in two and partial response in the other two
patients. Therapy results have been stable for at
least 18 months.Chemotherapy Response rate (%)
Doxorubicin (21) 10
Cisplatin (13) 16
Vinorelbine (14) 20
Paclitaxel+carboplatin (22) 14
Cyclophosphamide+
doxorubicin+cisplatin (15)
27–46
Cisplatin+doxorcin+5-FU (16) 35Discussion
Salivary gland tumours compromise approxi-
mately 3–4% of all head and neck carcinomas and
MEC is the most commonly reported histological
type. MEC is classified as low grade (well differ-
entiated) when composed of largely mucussecreting cells and as high grade (poorly differen-
tiated) when characterised by squamous cells with
rare mucus secreting cells.9 Low grade MEC have a
good prognosis with 5-year survival rates of about
90% and recurrences described in 1% of cases. High
grade MEC as a counterpart histologic feature
shows aggressive local behaviour, a local relapse
rate of 25% and a 5-year survival of below 30%.
Treatment is primarily surgical, especially in pa-
tients with an early stage of disease. Radiation
therapy alone has been used if poor cosmetic result
are expected with surgical resection or in patients
with advanced unresectable disease. The use of
adjunctive radiation has been reported to improve
loco-regional control but its influence on overall
survival is not clear.10;11
Clear indications for radiation are still involved
surgical margins, high risk histologic findings such
as high grade MEC or an advanced stage of dis-
ease.12
Chemotherapy is used in cases of locally ad-
vanced, metastatic or recurrent disease. Several
agents have been used and response rates vary
between 10 and 46% shown in Table 2. Vinorelbine
and Cisplatin are described as the most effective
single agents, with response rates of 20 and
16%.13;14 Combination therapy seems to be more
promising. Combinations of cyclophosphamid,
doxorubicin and cisplatin and of cisplatin, doxeru-
bicin and 5-FU gave response rates from 27 to 46%
and 35% respectively,15;16 but the increased side
effects have to be recognised. Docetaxel has shown
impressive anti-tumour activity in patients with
7Docetaxel (Taxotere) in MEC of salivary glandshead and neck cancer, especially in squamous cell
carcinoma.17;18 With its promising response rates,
this drug seems to be a logical alternative in sali-
vary gland tumours. Although anti-tumoural acti-
vity in an experimental context was found with
Docetaxel in murine salivary gland carcinoma,
there are only a few reports in clinical settings in
the literature.19;20Conclusion
In the patients reported excellent responses
were obtained after six cycles of docetaxel. The
treatment was well tolerated, showing a moderate
side effect profile. Confirmation of the value of the
treatment of salivary gland carcinoma may lead to
new therapeutic strategies.References
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